UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

Benzinga · 1d ago
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.